Search results
Results from the WOW.Com Content Network
Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another ...
9 Antiplatelet drug. 10 Anticoagulant. 11 Fibrinolytics. 12 Diuretics. 13 References. Toggle the table of contents. List of cardiac pharmaceutical agents. Add ...
Generally, drugs outlined within the ATC code B01AC should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiplatelet drugs .
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
The second generation thienopyridine P2Y 12 receptor blocker clopidogrel is an effective antiplatelet agent useful for treatment of ischemic cerebrovascular, cardiac and peripheral arterial release. [27] Like other thienopyridine drugs, the drug was often combined with aspirin in clinical use. [23]
In medicine, glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, is a class of antiplatelet agents. Several GpIIb/IIIa inhibitors exist: abciximab (abcixifiban) (ReoPro) eptifibatide (Integrilin) tirofiban (Aggrastat) roxifiban; orbofiban
Generally, drugs outlined within the ATC code B01 should be included in this category. Please see WP:PHARM:CAT for more information. The main article for this category is Antithrombotic agents .
Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar indications for use but is not a thienopyridine. It is a cyclo-pentyltriazolo-pyrimidine that is distinct from the mechanism of the thienopyridines in that it reversibly (rather than irreversibly) inhibits the P2Y 12 receptor.